Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SMMT Summit Therapeutics PLC

Market Closed 08-28 16:00:00 EDT

13.73

-0.60

-4.19%

盘后13.69

-0.04-0.27%

19:59 EDT

High14.24	Low13.43	Vol3.91M
Open14.11	D1 Closing14.33	Amplitude5.65%
Mkt Cap10.95B	Tradable Cap2.09B	Total Shares797.75M
T/O53.62M	T/O Rate2.56%	Tradable Shares152.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":13.73,"timestamp":1787947200000,"preClose":14.33,"halted":0,"volume":3906883,"hourTrading":{"tag":"盘后","latestPrice":13.6927,"preClose":13.73,"latestTime":"19:59 EDT","volume":56265,"amount":772219.9415,"timestamp":1787961562673,"change":-0.0373,"changeRate":-0.002717,"amplitude":0.010925},"delay":0,"changeRate":-0.04187020237264478,"floatShares":152343050,"shares":797749602,"eps":-1.117703,"marketStatus":"Market Closed","change":-0.6,"latestTime":"08-28 16:00:00 EDT","open":14.11,"high":14.24,"low":13.43,"amount":53624832.920239,"amplitude":0.056525,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.117703,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":14.33,"preHourTrading":{"tag":"盘前","latestPrice":14.1,"preClose":14.33,"latestTime":"09:27 EDT","volume":17626,"amount":250583.92434599999,"timestamp":1787923660009,"change":-0.23,"changeRate":-0.01605,"amplitude":0.026853},"postHourTrading":{"tag":"盘后","latestPrice":13.6927,"preClose":13.73,"latestTime":"19:59 EDT","volume":56265,"amount":772219.9415,"timestamp":1787961562673,"change":-0.0373,"changeRate":-0.002717,"amplitude":0.010925},"volumeRatio":0.569989430592612,"impliedVol":1.1675,"impliedVolPercentile":0.8566},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"2662671024","title":"Summit Therapeutics Inc Stock (SMMT) Moved Up by 8.95% on Aug 26: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2662671024","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662671024?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:15","pubTimestamp":1787753716,"startTime":"0","endTime":"0","summary":"• Summit Therapeutics shares rose following positive Phase 3 trial results for ivonescimab.\n• The HARMONi-GI1 study met its primary overall survival endpoint in biliary tract cancer.\n• Summit reports zero annual revenue and a net loss of $1.08 billion.","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262133421-market-movers-smmt-20260826","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662712851","title":"Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662712851?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:18","pubTimestamp":1787750291,"startTime":"0","endTime":"0","summary":"Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  declining by 0.5%.Boston Scientific  has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.Jazz Pharmaceuticals'  wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.Summit Therapeutics  partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","LU0029874061.USD","LU0345769631.USD","LU0225283273.USD","SMMT","LU0528227936.USD","BSX.AU","LU0109394709.USD","LU1989764664.SGD","LU1291159041.SGD","LU0077335932.USD","IE00BN0W2W23.USD","XLV","LU2488822045.USD","IE00BN0W2T93.GBP","LU2357305700.SGD","LU2362541273.HKD","LU0238689110.USD","LU2506951875.HKD","BK7095","JAZZ","BK4504","LU1061106388.HKD","LU2491050154.USD","HCSG","LU0128526141.USD","BK4082","IE0009355771.USD","LU0823416689.USD","BK4581","LU1791710400.SGD","LU0950375773.USD","BSX","LU0187121727.USD","LU0011850046.USD","LU1989772923.USD","XBI","LU2244417387.USD","LU2362541513.USD","IE0002141913.USD","LU0266013472.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU0823417653.USD","LU2491049909.HKD","LU0114720955.EUR","LU1153585028.USD","LU1989771016.USD","LABU","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662714742","title":"Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2662714742","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662714742?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:12","pubTimestamp":1787749945,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively traded Invesco QQQ Trust (QQQ) was 0.3% lower in Wednesday's premarket activity as July PCE inflation","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SJM","PMR","QQQ","IYJ","BITO","FDN","INTU","IBB","IVV","IPK","RTH","XSD","SFL","GLD","VIS","XLP","IWM","EQR","IYH","XLK","XLV","XLI","BETH","SMMT","IGM","XLE","XLY","IYK","VHT.AU","USO","TRUP","SOXX","SPY.AU",".IXIC","SLV","XLF","EXI","IYW","IYE","VDC","E","XRT","UNG","FAZ","BP","SPY","RTH.AU","VHT","EETH","FAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795041","title":"Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795041","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795041?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:16","pubTimestamp":1787732205,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer, Summit Therapeutics said late Tuesday.The ivonescimab-based regimen showed \"statistically significant and clinically meaningful superiority\" in the study's primary endpoint of overall survival, compared with the durvalumab-based regimen, the company said.The trial, conducted in China, also met its secondary endpoints of progression-free survival and objective response rate, according to Summit Therapeutics.The company's shares were up 4.5% in premarket activity Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","SMMT","BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775056","title":"Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775056?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:05","pubTimestamp":1787695512,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) noted that its partner Akeso announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-akeso-reports-positive-results-from-phase-iii-harmoni-gi11-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-akeso-reports-positive-results-from-phase-iii-harmoni-gi11-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2488822045.USD","III","BK4139","BK4134","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757420","title":"Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757420?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:00","pubTimestamp":1787695207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M111:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662574297","title":"Summit Therapeutics - Study Meets Key Secondary Endpoints of Pfs and Orr","url":"https://stock-news.laohu8.com/highlight/detail?id=2662574297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662574297?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:00","pubTimestamp":1787695207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M111:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","BK4139","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662364507","title":"Summit Says FDA Sets Nov. 14, 2026 Action Date for Ivonescimab Lung Cancer Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662364507","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662364507?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:00","pubTimestamp":1787655652,"startTime":"0","endTime":"0","summary":"Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filingSummit Therapeutics’ BLA for ivonescimab with platinum-doublet chemotherapy entered FDA review for EGFR-mutated advance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL3BvY4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660058433","title":"Summit Therapeutics falls -8.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660058433","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660058433?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:05","pubTimestamp":1786975525,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) is down -8.5%, or -$1.13 to $12.22. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-falls-8-5-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-falls-8-5-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2488822045.USD","BK4539","SMMT","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659812854","title":"EV targets set to be watered down","url":"https://stock-news.laohu8.com/highlight/detail?id=2659812854","media":"cityam","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659812854?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:08","pubTimestamp":1786720135,"startTime":"0","endTime":"0","summary":"The government announced the EV mandate review late on Friday Electric vehicle sales targets for British carmakers could be watered down after ministers launched a fresh review amid growing pressure from manufacturers and dealerships.The government said it was seeking the opinions of auto makers, suppliers and charging point providers on whether to loosen the ambitious plans to phase out sales of petrol and hybrid vehicles by 2035.As many of 80 per cent of car sales must be EVs by 2030 in the current EV pathway, in what is one of the most ambitious government-set transition plans among developed economies.EV review follows industry warningsThe Society of Motor Manufacturers and Traders  had previously said the policy, which forces carmakers to sell a growing share of electric cars each year, was “running ahead of market demand” and urgently needed to be watered down.","market":"us","thumbnail":"https://www.cityam.com/wp-content/uploads/2026/07/Carmakers-car-plant-uk-EVs.jpg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2026/07/Carmakers-car-plant-uk-EVs.jpg?w=824&h=463&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/ev-targets-set-to-be-watered-down/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/ev-targets-set-to-be-watered-down/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ZEV","SMMT","BK4149","CARD","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659320171","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659320171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659320171?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:30","pubTimestamp":1786609840,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sutro Biopharma (STRO), Summit Therapeutics (SMMT)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sutro-biopharma-stro-summit-therapeutics-smmt-and-altimmune-alt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sutro-biopharma-stro-summit-therapeutics-smmt-and-altimmune-alt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","STRO","LABU","LU2488822045.USD","BK4137","XBI","XLV","BK4588","LU0029874061.USD","BK4599","BK4585","BK4581","BK4139","ALT","HCSG","LU1878469433.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UFO","SLXN","CORD","EAT","ABSI","CIEN","HRB","UAMY","LOCL","DPRE","TRMB","SMCL","SVV","CAVA","HUMA","TECH","BETA","LITE","O","NBIS","WXM","CHTR","OFAL","NBIZ","SLN","TAN","PFGC","GAP","NTHI","TSHA","SLNCF","EROC","CRWV","ALT","SMMT","LQDA","ANNX","NBIX","STRO","FSLR","EGGY","NCMI","TPL","OPLN","DFTX","LUMA","BIVI","SMCI","SMWB","LAZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658906520","title":"Summit Partner Akeso Wins China NMPA Approval for Ivonescimab-Chemo in First-Line Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906520","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906520?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:20","pubTimestamp":1786548040,"startTime":"0","endTime":"0","summary":"Summit partner Akeso wins China NMPA approval for ivonescimab-chemo in first-line squamous NSCLCChina’s NMPA cleared Akeso’s ivonescimab with chemotherapy for first-line advanced squamous NSCLC, expan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL56kY3l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908461","title":"Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908461?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:42","pubTimestamp":1786542133,"startTime":"0","endTime":"0","summary":"BUZZ-Summit gains after partner Akeso secures China nod for lung cancer combo** Shares of Summit TherapeuticsSMMT.Orise 3% to $15.58** Co says its partner Akeso9926.HKannounced the marketing authoriza","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N44913L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1961090484.USD","LU2488822045.USD","LU1794554557.SGD","LU1720050803.USD","LU0417516571.SGD","LU0348735423.USD","LU0634319403.HKD","LU0348767384.USD","09926","LU0348783233.USD","LU0417516902.SGD","LU0348827113.USD","LU2778985437.USD","BK1574","LU0417516738.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348825331.USD","KURE","IE00B5MMRT66.SGD","LU0348766576.USD","LU2399975544.HKD","LU0348784397.USD","LU2476274720.SGD","LU0561508036.HKD","LU2476274308.USD","IE00B543WZ88.USD","SMMT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970062","title":"Ivonescimab in Combination with Chemotherapy Approved in China by Nmpa for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970062?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:22","pubTimestamp":1786540920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUABTXZDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658397953","title":"Summit Therapeutics Inc. : Leerink Partners Raises to Market Perform from Underperform; Raises Target Price to $13 from $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2658397953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658397953?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:38","pubTimestamp":1786531110,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490KU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152245445","title":"China's Automakers Capture Three Spots in UK July Best-Selling Top Ten","url":"https://stock-news.laohu8.com/highlight/detail?id=1152245445","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152245445?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:02","pubTimestamp":1786017730,"startTime":"0","endTime":"0","summary":"The UK car market saw a significant shift in July, with data from the British Society of Motor Manufacturers and Traders (SMMT) revealing that new car registrations reached 156,571 units, a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686617","title":"Barclays Remains a Hold on Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657686617?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:38","pubTimestamp":1786005506,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Hold rating on Summit Therapeutics today and set a price target of $18.00. Darout covers the Healthcare ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-summit-therapeutics-smmt-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-summit-therapeutics-smmt-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2488822045.USD","LABU","BK4588","XLV","BK4139","SMMT","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657490585","title":"Summit announces expansion of development program for ivonescimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2657490585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657490585?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:41","pubTimestamp":1785930107,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) announced the expansion of its global registration-enabling clinical development program for the novel, potential first-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-announces-expansion-of-development-program-for-ivonescimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-announces-expansion-of-development-program-for-ivonescimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMT","LU2488822045.USD","SMMF","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657546541","title":"Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial of Ivonescimab in Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657546541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657546541?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:08","pubTimestamp":1785928114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4420R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":0.0433},{"period":"1month","weight":0.0727},{"period":"3month","weight":-0.2172},{"period":"6month","weight":-0.1724},{"period":"1year","weight":-0.4378},{"period":"ytd","weight":-0.215}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.0357},{"month":3,"riseRate":0.454545,"avgChangeRate":0.039344},{"month":4,"riseRate":0.5,"avgChangeRate":0.042597},{"month":5,"riseRate":0.5,"avgChangeRate":0.075963},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.093606},{"month":7,"riseRate":0.583333,"avgChangeRate":0.072153},{"month":8,"riseRate":0.5,"avgChangeRate":-0.001875},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC","securityTypeName":"DR","adrRate":"1:5"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Summit Therapeutics PLC(SMMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Summit Therapeutics PLC(SMMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}